In contrast, Pillai et al., 2022 [89], showed significantly increased levels of cTnI at 6 months and cTnT at 3 and 6 months of trastuzumab treatment (with or without pertuzumab) in combination with paclitaxel or docetaxel (with or without carboplatin) in HER2-positive breast cancer patients (n = 17, p < 0.05) compared to the healthy controls (n = 17). This evidence concerns the gene TNNT2 and breast cancer.